Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Price Wins Confirmation As US Health Secretary; Verma On Deck For CMS Hearing

Executive Summary

Senators voted 52 to 47 to confirm Rep. Tom Price, R-Ga., as Health and Human Services secretary, where he will be a key leader implementing reversals to the Affordable Care Act. Meanwhile, Trump’s pick to lead the Medicare agency, Seema Verma, faces a confirmation hearing in the Senate Feb. 16.

You may also be interested in...

HHS Nominee Vote Delayed By Senate Dem Boycott

Senate Finance Committee Ranking Member Ron Wyden led other panel Democrats in boycotting a planned Jan. 31 vote on the confirmation of Rep. Tom Price as HHS Secretary. Wyden said the nominee "misled the public" and held back information on discounted shares of an Australian biomedical firm he bought. Committee Chair Orrin Hatch, R-Utah, was surprised by the setback to President Trump's nominee, and swore to bring Senate Democrats back to the committee to "do their job.”

Grassley Asks Price To Preserve 'Open Payments' Database

Sen. Chuck Grassley, R-Iowa, urged US Department of Health and Human Services secretary nominee Tom Price to preserve the "Open Payments" database that was established by Grassley's Physician Payment Sunshine Act, even if the Affordable Care Act, by which the Sunshine law was enacted, is repealed.

Price 'Not Aware' Of Stock Choices During HIP Act Consideration, He Tells Senators

HHS Secretary Nominee Rep. Tom Price, R-Ga., told members of a key Senate health panel that he was "not aware" of purchases his broker made of stocks in health-care companies including Zimmer Biomet Holdings Inc., shortly after introducing The HIP Act to delay a CMS orthopedics bundled payment program. The appointee also signaled his intentions 'not to pull the rug out' on millions of Americans' insurance coverage in any Affordable Care Act replacement plan he works on.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts